Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
P. O'Neill and
Consulting Reports from Office of Health Economics
This OHE Consulting Report reviews "Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS." The project was funded by the ABPI. For the year 2015/16, the Treasury reported growth in Government funded healthcare expenditure in the UK of 4.0% whilst NHS Digital reported medicines expenditure growth for the English National Health Service (NHS) for the same period at 8.0%. However, NHS Digital reported much reduced medicines expenditure growth for England of 3.5% for 2016/17, suggesting a complex underlying picture. NHS Digital growth rates are at list price as NHS Digital is not able to take account of rates of discount obtained by the NHS, which our analysis suggests are increasing, or of the rebate payments for branded drugs under the 2014-18 Pharmaceutical Price Regulation Scheme (PPRS). It is important to stress that we are analysing data to understand trends since 2014. This work does not allow us to make any predictions about future trends.
Keywords: Economics of innovation; Judging value for money and improving decision making (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
https://www.ohe.org/system/files/private/publicati ... 2018%20%28002%29.pdf (application/pdf)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:ohe:conrep:002051
Access Statistics for this paper
More papers in Consulting Reports from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ().